Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.

AI partners Microsoft and OpenAI’s cooling relationship cools further with Amgen’s switch from Copilot to ChatGPT.

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Corporates don't want Copilot Software King of the World, Microsoft is finding out the hard way that even a decades-long grip ...